Sundar Shyam, Sane Rohit Mahesh, Sundaramoorthy Raghulraj, Ashraf Munis, Rajan David V
Department of Shoulder and Elbow Surgery, Ortho-One Orthopaedic Specialty Centre, Coimbatore, India.
Department of Orthopaedics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, India.
Clin Shoulder Elb. 2025 Feb;28(1):23-30. doi: 10.5397/cise.2024.00556. Epub 2024 Nov 28.
This retrospective observational study compared outcomes of arthroscopic rotator cuff surgery using double row anchor repair (DRR) versus transosseous anchorless repair (TAR) in patients with small to large full-thickness rotator cuff tears.
A total of 42 patients underwent DRR (n=20) or TAR (n=22) between January 2022 and May 2023. Patients were matched based on age, sex, body mass index, and tear severity. Baseline demographics, including diabetes, smoking status, and Cofield classification, were compared. Functional outcomes were assessed using University of California, Los Angeles (UCLA) and American Shoulder and Elbow Surgeons (ASES) scores, along with range of motion (ROM) parameters: forward flexion, extension, internal rotation, external rotation, and abduction.
Baseline characteristics were similar between groups (P>0.05). TAR showed higher UCLA scores at 3 and 6 months (P<0.001) and superior ASES scores at 3 (P=0.025) and 6 months (P<0.001) compared to DRR. By 1 year, no significant differences were observed in UCLA (P=0.101), ASES (P=0.051), or ROM parameters (P>0.05).
Both DRR and TAR showed comparable outcomes at 1 year. However, TAR demonstrated early functional benefits at 3 and 6 months, indicating potential advantages in the initial recovery phase. Level of evidence: III.
这项回顾性观察研究比较了在小至大的全层肩袖撕裂患者中，使用双排锚钉修复（DRR）与经骨无锚钉修复（TAR）进行关节镜下肩袖手术的结果。
2022年1月至2023年5月期间，共有42例患者接受了DRR（n = 20）或TAR（n = 22）治疗。根据年龄、性别、体重指数和撕裂严重程度对患者进行匹配。比较了包括糖尿病、吸烟状况和科菲尔德分类在内的基线人口统计学特征。使用加利福尼亚大学洛杉矶分校（UCLA）和美国肩肘外科医师学会（ASES）评分以及活动范围（ROM）参数：前屈、后伸、内旋、外旋和外展来评估功能结果。
两组之间的基线特征相似（P>0.05）。与DRR相比，TAR在3个月和6个月时的UCLA评分更高（P<0.001），在3个月（P = 0.025）和6个月时的ASES评分更高（P<0.001）。到1年时，UCLA（P = 0.101）、ASES（P = 0.051）或ROM参数（P>0.05）均未观察到显著差异。
DRR和TAR在1年时的结果相当。然而，TAR在3个月和6个月时显示出早期功能益处，表明在初始恢复阶段具有潜在优势。证据级别：III级。
